CN101535282A - 3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐 - Google Patents

3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐 Download PDF

Info

Publication number
CN101535282A
CN101535282A CNA2007800406691A CN200780040669A CN101535282A CN 101535282 A CN101535282 A CN 101535282A CN A2007800406691 A CNA2007800406691 A CN A2007800406691A CN 200780040669 A CN200780040669 A CN 200780040669A CN 101535282 A CN101535282 A CN 101535282A
Authority
CN
China
Prior art keywords
oxalate
formula
medicine
compound
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800406691A
Other languages
English (en)
Chinese (zh)
Inventor
法比欧·纳加尼
劳拉·迪尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abiogen Pharma SRL
Original Assignee
Abiogen Pharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abiogen Pharma SRL filed Critical Abiogen Pharma SRL
Publication of CN101535282A publication Critical patent/CN101535282A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2007800406691A 2006-11-02 2007-10-31 3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐 Pending CN101535282A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002102A ITMI20062102A1 (it) 2006-11-02 2006-11-02 Nuovui sali di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidrobenzo-d-isossazol-4-one
ITMI2006A002102 2006-11-02

Publications (1)

Publication Number Publication Date
CN101535282A true CN101535282A (zh) 2009-09-16

Family

ID=39145485

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007800406691A Pending CN101535282A (zh) 2006-11-02 2007-10-31 3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐
CNA2007800406598A Pending CN101535281A (zh) 2006-11-02 2007-10-31 3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007800406598A Pending CN101535281A (zh) 2006-11-02 2007-10-31 3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐

Country Status (20)

Country Link
US (2) US20100069451A1 (https=)
EP (2) EP2094674B1 (https=)
JP (2) JP2010509310A (https=)
KR (2) KR20090082452A (https=)
CN (2) CN101535282A (https=)
AT (2) ATE504578T1 (https=)
AU (2) AU2007315832A1 (https=)
BR (2) BRPI0718391A2 (https=)
CA (2) CA2667515A1 (https=)
DE (2) DE602007013801D1 (https=)
HR (2) HRP20090477A2 (https=)
IL (2) IL198444A0 (https=)
IT (1) ITMI20062102A1 (https=)
MX (2) MX2009004294A (https=)
NO (2) NO20092115L (https=)
NZ (2) NZ577311A (https=)
RS (2) RS20090389A (https=)
RU (2) RU2009120667A (https=)
WO (2) WO2008053325A1 (https=)
ZA (2) ZA200903618B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2112142A1 (en) * 2008-04-24 2009-10-28 Abiogen Pharma S.p.A. Process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one
ITMI20080768A1 (it) * 2008-04-24 2009-10-25 Abiogen Pharma Spa Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
EP2218721A1 (en) * 2009-02-11 2010-08-18 LEK Pharmaceuticals d.d. Novel salts of sitagliptin
WO2011010332A1 (en) * 2009-07-23 2011-01-27 Abiogen Pharma S.P.A. Process for preparing rel-(3r*,3as*,7as*)-3-benzyl-2-methyl-2,3, 3a,4,5,6,7,7a- octahydrobenzo[d]isoxazoi-4-one or a salt thereof
WO2016123275A1 (en) * 2015-01-30 2016-08-04 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161595A (en) * 1978-10-02 1979-07-17 Bristol-Myers Company Levulinic acid salt
US4419358A (en) * 1981-11-12 1983-12-06 Mead Johnson & Company Isethionic acid salt of 9-cyclohexyl-2-propoxy-9H-purine-6-amine and compositions containing an effective bronchodilating concentration of it
GB2264299B (en) * 1992-02-19 1995-07-26 British Tech Group Iso-oxazolidine derivatives

Also Published As

Publication number Publication date
KR20090077014A (ko) 2009-07-13
US20100069451A1 (en) 2010-03-18
WO2008053326A1 (en) 2008-05-08
NZ577978A (en) 2010-10-29
EP2094675A1 (en) 2009-09-02
JP2010509310A (ja) 2010-03-25
MX2009004294A (es) 2009-05-08
RS20090389A (sr) 2010-12-31
WO2008053325A1 (en) 2008-05-08
JP2010509309A (ja) 2010-03-25
HRP20090470A2 (hr) 2009-11-30
MX2009004293A (es) 2009-05-08
ATE502021T1 (de) 2011-04-15
IL198444A0 (en) 2010-02-17
ITMI20062102A1 (it) 2008-05-03
AU2007315832A1 (en) 2008-05-08
RS20090388A (sr) 2010-12-31
NO20092115L (no) 2009-05-29
RU2009120667A (ru) 2010-12-10
CA2667515A1 (en) 2008-05-08
RU2009120724A (ru) 2010-12-10
KR20090082452A (ko) 2009-07-30
ZA200903810B (en) 2010-07-28
AU2007315833A1 (en) 2008-05-08
IL198443A0 (en) 2010-02-17
EP2094675B1 (en) 2011-04-06
HRP20090477A2 (hr) 2009-11-30
NO20092114L (no) 2009-05-29
ZA200903618B (en) 2010-07-28
DE602007013801D1 (de) 2011-05-19
US20100069450A1 (en) 2010-03-18
BRPI0718392A2 (pt) 2013-11-26
CA2667513A1 (en) 2008-05-08
DE602007013278D1 (de) 2011-04-28
ATE504578T1 (de) 2011-04-15
NZ577311A (en) 2010-10-29
CN101535281A (zh) 2009-09-16
BRPI0718391A2 (pt) 2013-11-26
EP2094674B1 (en) 2011-03-16
EP2094674A1 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
CA2976634C (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
EP0506532A1 (fr) Nouveaux dérivés de l'indole, procédé de préparation et médicaments les contenant
OA12165A (fr) Dérivés aminés de dihydro-1,3,5-triazine et leurs applications en thérapeutique.
CN101535282A (zh) 3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐
US20100120746A1 (en) Use of r-10-hydroxy-10,11-dihydro-carbamazepine in neuropathic pain
FR2822464A1 (fr) Derives biguanides et leurs applications en therapeutique
CA2898450A1 (en) Isometheptene isomer
EP4149479A1 (en) Sterols in the treatment and/or prevention of sars-cov-2 infection
CN114349745B (zh) 一种用于治疗心肌缺血的药物及其制备方法
JP6279773B2 (ja) ロイコトリエン受容体拮抗薬として用いるシクロプロピル不飽和キノリン化合物及びその使用
CA3048346A1 (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease
EP0743063B1 (fr) Utilisation de dérivés d'alpha-aminométhyl-3-4-dichlorobenzyl thioacétamide pour la fabrication d'un médicament inhibant la recapture de la dopamine et nouveaux composés pour cette utilisation
EP2931266A1 (fr) Composition et kit comprenant des dérivés de pipérazine et de la metformine, leur utilisation dans le traitement du diabète
WO2012175715A1 (fr) Dérivés de pipérazine, leurs procédés de préparation et leurs utilisations dans le traitement de l'insulinorésistance
EP0226511A1 (fr) Dérivés de 5-phényl-1,4,5,6-tétrahydropyrimidine, procédé de préparation et utilisation en thérapeutique
JP2003267868A (ja) ヒドロキシ脂肪酸類縁体を有効成分とするマラリア感染症の予防および治療剤
JP2000053620A (ja) 芳香族抗真菌剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20090916

C20 Patent right or utility model deemed to be abandoned or is abandoned